November 2016

Feature

Lessons From Change Management Theory for the Implementation of Clinical Pathways

11/15/2016

Tobias Romeyke, PhD

Elisabeth Nöhammer, DHSc

Harald Stummer, PhD

Performance-based models for health care reimbursement are designed to promote and reward an efficient allocation of resources as well as to ensure quality.1 One such model is based on adherence to predetermined...

...

11/15/2016

Journal of Clinical Pathways

Feature

Defining Target Populations for Clinical Pathways

11/15/2016

David Hughes, BSN

A critical consideration in pathway development is identification of the target population for the pathway. A pathway is often developed for a specific population of patients with a given clinical diagnosis. However,...

A...

11/15/2016

Journal of Clinical Pathways

Column

Clinical Pathways GPS

Sites of Care: An Opportunity to Address Efficiency and Effectiveness in Clinical Pathways

11/15/2016

Richard G Stefanacci, DO, MGH, MBA, AGSF, CMD—Column Editor

As our health system increases the financial responsibility of health care providers, there is increased focus among these providers on reducing costs. Part of this cost-reduction effort involves improving the...

As our...

11/15/2016

Journal of Clinical Pathways

Pharma Insights

Creating Room to Show Value of New Products When Good Enough Treatments Exist

11/15/2016

Dan Renick, RPh

Larry Blandford, PharmD—Column Editor

Traditional markets have grown crowded with acceptable treatments for large patient populations, which can limit access for drugs in development for these therapeutic areas. Rather than taking a head-on approach to...

...

11/15/2016

Journal of Clinical Pathways

Insights

Interview

ACS CAN Addresses Controversy Surrounding Opioids

11/15/2016

Mark Fleury, PhD, MS

An interview with Mark Fleury, PhD, MS, principal, Policy Development, Emerging Science, American Cancer Society Cancer Action Network, Washington, DC.  Pain as a result of cancer or cancer treatment...

An...

11/15/2016

Journal of Clinical Pathways

Interview

Making Decisions About New Cancer Treatments With Limited Evidence

11/15/2016

Jim C Hu, MD, MPH

An interview with Jim C Hu, MD, MPH, urologic oncologist and director of the LeFrak Center for Robotic Surgery at NewYork-Presbyterian and Weill Cornell Medicine, New York, NY.  Prostate cancer...

An...

11/15/2016

Journal of Clinical Pathways

Department

Research in Review

Review Examines Prognostic Value of Tumor-Infiltrating Lymphocytes in Early Breast Cancer

11/15/2016

JCP Editors

Tumor-infiltrating lymphocytes (TILs) have been described in various tumors, including breast cancer. In early breast cancer, the presence of TILs is associated with better outcomes and response to therapy. A review...

...

11/15/2016

Journal of Clinical Pathways

Research in Review

Analysis Finds Tocilizumab Superior to Conventional DMARDs in RA

11/15/2016

JCP Editors

A comparative effectiveness analysis of biologics for rheumatoid arthritis (RA) showed that tocilizumab monotherapy and tocilizumab plus methotrexate were superior to conventional disease-modifying antirheumatic...

A...

11/15/2016

Journal of Clinical Pathways

Research in Review

Chest Pain Clinical Pathway in Pediatric ED Can Influence Resource Use

11/15/2016

JCP Editors

Because most young children are not able to accurately describe or localize their pain, ruling out cardiac disease in children can be challenging, leading to increased health care utilization for chest pain...

...

11/15/2016

Journal of Clinical Pathways

Research in Review

Pediatric Stroke Pathway Improves Time to Definitive Diagnosis

11/15/2016

JCP Editors

A pediatric stroke clinical pathway significantly improved time to definitive diagnosis while also streamlining the care provided to children presenting to the pediatric emergency department (ED) with focal...

A...

11/15/2016

Journal of Clinical Pathways

Current Issue

June 2024

Volume 10

Issue 3

Current Issue

Issue Archive

Special Reports

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Winston Wong, PharmD

Gordon Kuntz

Robin T Zon, MD, FACP, FASCO

2021 Care Pathways Working Group

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

$Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma$

Special Report

Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma

01/14/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Editorial Correspondence

November 2016

Column

Insights

Department

Current Issue

Special Reports

Subscribe

November 2016 Volume 2

Specialties

Events

Year Round Education

HMP Global Products